ArticleJournal of gynecologic oncology2018
Baseline risk of recurrence in stage I-II endometrial carcinoma.
Article in Journal of gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 53 citations in OpenAlex.
- Mesenteric desmoid tumor after laparoscopic resection of stage I endometrial cancer: A case report.Case reports in women's health · 2025Article
- Machine learning models using multiparametric MRI for preoperative risk stratification in endometrial cancer.American journal of cancer research · 2024Article
- Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia.Archives of gynecology and obstetrics · 2023Article
- Article
- Pulmonary metastasis of stage I, low-grade endometrioid carcinoma: two case reports and the literature review.Frontiers in oncology · 2023Article
- Metastatic Endometrioid Carcinoma Mimicking a Subungual Melanoma.International journal of environmental research and public health · 2022Article
- The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
- Risk Factors and Prognosis of Early Recurrence in Stage I-II Endometrial Cancer: A Large-Scale, Multi-Center, and Retrospective Study.Frontiers in medicine · 2022Article
- Effects of BMI1 Gene on Regulating Apoptosis, Invasion, and Migration of HEC-1B Cells Induced by Ionizing Radiation.Journal of healthcare engineering · 2022Article
- Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer.Cancer medicine · 2021Article
- The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer.Gynecologic oncology reports · 2021Article
- Analysis of Prognostic Factors and Treatment Modes of Patients with Recurrent Endometrial Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Prognostic significance of lymphovascular space invasion in patients with endometrioid endometrial cancer: a retrospective study from a single center.Journal of gynecologic oncology · 2020Article
- Adjuvant chemotherapy in endometrial cancer.Cancer chemotherapy and pharmacology · 2020Review
- Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer.Journal of clinical medicine · 2020Article
- Nomogram for Predicting Recurrence-Free Survival in Chinese Women with Endometrial Cancer after Initial Therapy: External Validation.Journal of oncology · 2020Article
- A Novel Predictive Tool for Determining the Risk of Early Death From Stage IV Endometrial Carcinoma: A Large Cohort Study.Frontiers in oncology · 2020Article
- A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma.Journal of gynecologic oncology · 2019Article
- The Potential Value of Ki-67 in Prognostic Classification in Early Low-Risk Endometrial Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThough there are no evidences that postoperative therapy improves overall survival (OS) in stage I-II endometrial carcinoma, many women receive postoperative radiation or chemotherapy. This study aimed to investigate the baseline risk of recurrence after complete resection without any adjuvant therapies and to suppose the validity of postoperative therapy for stage I-II endometrial carcinoma.
methodsCharts for patients with stage I-II endometrial carcinoma who underwent operation without postoperative therapy between January 2005 and December 2011 were retrospectively reviewed and the baseline risk of recurrence and prognosis were assessed. Risk classifications were performed according to European Society for Medical Oncology (ESMO) clinical practice guidelines and Japanese guideline written by Japan Society of Gynecologic Oncology Group.
resultsAmong 374 patients who underwent complete resection, 311 were evaluable. Five-year recurrence rates by ESMO and Japanese were 2.6% and 3.1% in low-risk, 9.2% and 6.6% in intermediate-risk and 13.5% and 13.8% in high-risk group (p=0.003 and 0.015, respectively). High-risk group had worse OS compared with low- and intermediate-risk groups (5-year OS, low: 97.9% and 97.6%, intermediate: 97.9% and 98.8%, and high: 89.5% and 87.5%; p=0.003 and 0.008, respectively). Independent predictive factors of recurrence were age over 60 years, type 2 (estrogen-independent) and peritoneal cytology.
conclusionESMO and Japanese risk classification similarly stratify the baseline risk of recurrence. Patients with stage I-II endometrial carcinoma, especially low- and intermediate-risk diseases, have low recurrence rate and favorable OS, and the benefit of postoperative therapy might be small.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.